Advances in home-based respiratory muscle training for improving physical function in older adults with long COVID.

Advances in home-based respiratory muscle training for improving physical function in older adults with long COVID.

Publication date: Jul 11, 2025

Long COVID imposes a substantial burden on older adults, manifesting as respiratory muscle dysfunction that severely compromises physical function. This narrative review synthesizes current evidence on home-based respiratory muscle training (RMT)-a non-pharmacological intervention targeting this impairment in older patients with long COVID-while critically evaluating its physiological mechanisms, therapeutic efficacy, implementation feasibility, and persistent challenges. Respiratory muscle dysfunction, caused by multifaceted neurophysiological and structural impairments, is a core mechanism of exertional dyspnea and fatigue in older adults, further aggravated by age-related decline. RMT mitigates these effects through improvements in respiratory strength, endurance, ventilatory efficiency, metaboreflex and autonomic regulation, and psychological wellbeing. Home-based RMT demonstrates non-inferior efficacy to conventional programs while providing critical accessibility for mobility-limited older adults. Nevertheless, implementation barriers include challenges in individualizing geriatric-adapted exercise prescriptions, technological access limitations, variable adherence, insufficient clinician training in remote assessment, and regulatory/policy gaps in telerehabilitation frameworks. Despite these challenges, home-based RMT represents a promising strategy for managing debilitating respiratory sequelae in this vulnerable population. This review consolidates RMT’s physiological rationale and clinical evidence, underscores its integration potential within collaborative care models, and outlines key translational priorities-including hybrid delivery systems and refined geriatric-specific protocols-to accelerate clinical adoption.

Open Access PDF

Concepts Keywords
Adults long covid
Endurance older adults
Geriatric physical function
Home telerehabilitation
Neurophysiological

Semantics

Type Source Name
disease MESH long COVID
disease IDO intervention
disease MESH dyspnea
disease MESH sequelae
drug DRUGBANK Coenzyme M
drug DRUGBANK Guanosine
pathway REACTOME Reproduction
disease MESH COVID 19 pandemic
disease MESH fibrosis
disease MESH defects
disease MESH hypertension
disease MESH Critical illness
disease MESH lung injury
disease MESH drug induced myopathy
disease MESH musculoskeletal pain
disease MESH depression
disease MESH anxiety
disease MESH infection
disease MESH clinical course
disease MESH arthralgia
disease MESH insomnia
disease IDO entity
disease IDO role
pathway REACTOME Translation
disease MESH syndrome
disease MESH respiratory diseases
disease IDO quality
disease MESH obesity
disease MESH physical inactivity
disease MESH chronic conditions
disease MESH convalescence
disease MESH hypoxemia
disease MESH tachypnea
disease MESH pathological processes
disease MESH arc
drug DRUGBANK 3 7 11 15-Tetramethyl-Hexadecan-1-Ol
disease MESH tachycardia
disease MESH dysautonomia
drug DRUGBANK Oxygen
disease MESH chronic obstructive pulmonary disease
disease MESH asthma
pathway KEGG Asthma
disease MESH bronchiectasis
disease MESH hypertrophy
disease MESH acidosis
disease MESH clinical relevance
disease MESH symptom burden
disease MESH sarcopenia
disease MESH atrophy
disease IDO production
drug DRUGBANK Isoxaflutole
disease IDO symptom
disease MESH functional status
disease MESH mobility limitations
disease MESH privacy
disease MESH living alone
disease MESH frailty
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK D-Alanine
disease MESH cardiovascular disease

Original Article

(Visited 10 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *